On this page
Back to topBraveheart Bio BRVE
Braveheart Bio listed on Nasdaq on 6 Aug 2026 and is not in the S&P 500. It is worth $1.7 billion. Its price history starts on 7 Aug 2026. 9 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 2 other officers are on file.
- CEO
- Travis Murdoch
- Listed
- 6 Aug 2026 on Nasdaq, IPO filings and terms
- Headquarters
- San Francisco, CA
- Market cap
- $1.7B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Braveheart Bio's market cap since August 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $1.8B |
Download Braveheart Bio's data as JSON, with the weekly market caps in billions of dollars from 7 Aug 2026.
Board and leadership
Board and officers
1 person here also holds roles at other S&P 500 companies.
Roles filed up to 30 Sep 2026
| Name | Title |
|---|---|
| Directors (9) | |
| Travis MurdochCEO and President | |
| Vineeta AgarwalaDirector | |
| Jasper BosDirector | |
| Erez ChimovitsDirector | |
| Jason V. ColomaDirector | |
| Tim LohoffDirector | |
| David Charles LubnerDirector | |
| David I. MalekDirector | |
| Christopher ViehbacherDirectorAlso at Biogen | |
| Officers (2) | |
| James Paul RickeyChief Financial OfficerLast filed 7 Aug 2026 | |
| Michele A. AndersonChief Development OfficerLast filed 7 Aug 2026 | |
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $39.5 million in 7 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 7 Aug 2026Buy | Erez ChimovitsDirector | $35M |
| 7 Aug 2026Buy | Christopher ViehbacherDirector | $1.5M |
| 7 Aug 2026Buy | Travis MurdochCEO and President | $1.5M |
| 7 Aug 2026Buy | David Charles LubnerDirector | $1000K |
| 7 Aug 2026Buy | James Paul RickeyChief Financial Officer | $500K |
| 7 Aug 2026Buy | David I. MalekDirector | $75K |
| 7 Aug 2026Buy | Michele A. AndersonChief Development Officer | $20K |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: Braveheart Bio listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.